Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1315 - Clinical outcome of ifosfamide in combination with carboplatin in small cell lung cancer: Results from third- or further- line chemotherapy (500P)


18 Nov 2017


Poster lunch


Myoungrin Park


Annals of Oncology (2017) 28 (suppl_10): x153-x154. 10.1093/annonc/mdx674


M. Park, J. Lee

Author affiliations

  • Department Of Internal Medicine, Division Of Pulmonology, Chungnam National University Hospital, 301-721 - Daejeon/KR


Abstract 1315


The number of available regimens which can be used in relapsed small-cell lung cancer (SCLC) is small and the data of the regimens is lack than those of non-small cell lung cancer. The goal of the present study is to evaluate the clinical outcome of ifosfamide and carboplatin (IC) regimen for third- or further-line chemotherapy in SCLC patients.


A retrospective analysis was conducted of all patients who received combination chemotherapy with IC regimenbetween 2011 and 2015 for SCLC. The data included baseline demographics, chemotherapy-related toxicities, therapeutic regimens that used and survival period.


A total of 12 patients were administered IC regimen. All of the IC regimens were used in third- or further-line chemotherapy and 9 (75%) of cases were fourth-line therapy. Of the 37 chemotherapy-related toxicity events, 27 (73%) were hematologic toxicities and thrombocytopenia (n = 10 (27%)) was reported most frequently. The median overall survival (OS) after IC administration was 3.5 months. Patients with positive change of body mass index (BMI) before IC administration (p = 0.071), without multiple metastases at start of IC regimen (p = 0.001), refractory relapse after first line treatment (p = 0.082), partial response or stable disease to the IC treatment (p = 0.007) showed longer duration of OS.Table: 500P

Patient characteristics (n = 12) at diagnosis and point of IC administration

Male10 (83.3%)
Pre-IC age: median (range)59 (43-67) years
00 (0%)
14 (33.3%)
27 (58.3%)
31 (8.3%)
40 (0%)
SMK: median (range)40 (0-80) packyears
BMI: median (range)
at diagnosis23.31 (16.93-31.75) kg/m2
pre-IC23.07 (18.58-29.79) kg/m2
Pre-IC albumiin: median (range)3.75 (3.3-4.1) mg/dL
Pre-IC LDH: median (range)510.50 (367-1245) U/L
Pre-IC Sodium: median (range)135.70 (125.60- 138.50) mEq/L
Pre-IC Hb: median (range)11.30 (9.3-13.4) g/dL
TNM staging at diagnosis
IIIB2 (16.7%)
IV10 (83.3%)
VALG staging at diagnosis
LD2 (16.7%)
ED10 (83.3%)
Multiple metastases at start of IC regimen
No5 (41.7%)
Yes7 (58.3%)
Type of relapase after 1st line treatment
Sensitive6 (50%)
Refractory6 (50%)
Response to IC regimen
CR0 (0%)
PR2 (16.7%)
SD1 (8.3%)
PD9 (75%)
Initial treatment method
CCRTx2 (16.7%)
CTx10 (83.3%)
Line of therapy that IC regimen used
3rd2 (16.7%)
4th9 (75%)
5th1 (8.3%)


The IC regimen is a reasonable therapeutic arm for relapsed SCLC.

Clinical trial identification

Legal entity responsible for the study

Myoungrin Park




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.